O'Neill was most recently chief medical officer at Sarepta Therapeutics.
Antisense oligonucleotide therapies to increase gene expression for the treatment of severe genetic diseases. Lead candidate in Dravet Syndrome (Image: Stoke Therapeutics).
In the short run, there may be a pause in this tech rally but that's not a given because the longer-term monster move is still there.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
| Website: | www.sarepta.com |
| Email: | iestepan@sarepta.com |
| Main Phone: | +1 617 274-4000 |
| Address: | 215 First Street |
| Address 2: | Suite 415 |
| State: | MA |
| City / Town: | Cambridge |
| Country: | US |
| Postal Code: | 02142 |
| Exchange: | NGS |
| CEO: | Douglas S. Ingram |
| Employees: | 866 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
O'Neill was most recently chief medical officer at Sarepta Therapeutics.
Antisense oligonucleotide therapies to increase gene expression for the treatment of severe genetic diseases. Lead candidate in Dravet Syndrome (Image: Stoke Therapeutics).
In the short run, there may be a pause in this tech rally but that's not a given because the longer-term monster move is still there.
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report, Chen
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the
Excellent diligence doesn't always mean you'll be saved from a nasty surprise. The nature of investing in biotech means assuming the risk that a therapeutic development program may fail.
The trend of the market has been relentlessly higher since the start of the new Bull Market way back in March 2009. The trend is your friend, and all of the forces that have created this Bull
Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of
Starting a new investment company and investing in very small biotechs can be a minefield. Because the business is fraught with bad science and liquidity traps, it takes insight and industry
The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
